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Abstract
Background: Oral rehydration salts (ORS), zinc, and continued feeding are the recommended treatments for
community-acquired acute diarrhea among young children. However, probiotics are becoming increasingly popular
treatments for diarrhea in some countries. We sought to estimate the effect of probiotics on diarrhea morbidity
and mortality in children < 5 years of age.
Methods: We conducted a systematic review of randomized controlled trials to estimate the effect of probiotic
microorganisms for the treatment of community-acquired acute diarrhea in children. Data were abstracted into a
standardized table and study quality was assessed using the Child Health Epidemiology Reference Group (CHERG)
adaption of the GRADE technique. We measured the relative effect of probiotic treatment in addition to
recommended rehydration on hospitalizations, duration and severity. We then calculated the average percent
difference for all continuous outcomes and performed a meta-analysis for discrete outcomes.
Results: We identified 8 studies for inclusion in the final database. No studies reported diarrhea mortality and
overall the evidence was low to moderate quality. Probiotics reduced diarrhea duration by 14.0% (95% CI: 3.8-
24.2%) and stool frequency on the second day of treatment by 13.1% (95% CI: 0.8 – 25.3%). There was no effect on
the risk of diarrhea hospitalizations.
Conclusion: Probiotics may be efficacious in reducing diarrhea duration and stool frequency during a diarrhea
episode. However, only few studies have been conducted in low-income countries and none used zinc (the
current recommendation) thus additional research is needed to understand the effect of probiotics as adjunct
therapy for diarrhea among children in developing countries.
Background
Diarrhea remains the second leading cause of death
among children 1-59 months of age [1]. Currently,
WHO recommends treatment with oral rehydration
salts (ORS) and continued feeding for the prevention
and treatment of dehydration, as well as zinc to shorten
the duration and severity of the episode [2]. Probiotics
are not recommended by WHO for the treatment of
community-acquired acute diarrhea, though they are
becoming increasingly popular in some countries [3].
Probiotics are non-pathogenic live microorganisms.
When ingested, probiotics can survive passage through
the stomach and small bowel [4]. They compete with
enteric pathogens for available nutrients and bacterial
adhesion sites, increase the acidity of the intestinal
environment, synthesize compounds that destroy or
inhibit pathogens, and may stimulate the host’s immune
response to invading pathogens [4,5].
In previous meta-analyses of the efficacy of probiotic
treatment for acute diarrhea in children, authors
restricted their searches to specific probiotic strains
[6-8]. A 2010 Cochrane systematic review of the use of
probiotics for the treatment of acute diarrhea found a
significant reduction in the mean duration of diarrhea
(24.76 hrs; 95% CI 15.91 - 33.61 hrs) and stool fre-
quency on the second day of treatment (mean difference
0.80; 95% CI 0.45 -1.14) [3]. In the Cochrane review,
authors did not limit their searches to a particular
strain, but included both adults and children in the
study population and studies that limited inclusion to
one etiology (e.g., only children with stools positive for
rotavirus).* Correspondence: cfischer@jhsph.edu
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We sought to conduct a systematic review and meta-
analysis of all probiotics for the treatment of commu-
nity-acquired acute diarrhea specifically among children
< 5 years of age. This systematic review was conducted
to examine the efficacy of probiotics in diarrhea treat-
ment and was designed to meet the needs of the Lives
Saved Tool (LiST) [9].
Methods
We conducted a systematic literature review to identify
randomized controlled trials (RCT) of probiotics for the
treatment of community-acquired acute diarrhea among
children < 5 years of age. We employed the Child
Health Epidemiology Reference Group (CHERG) guide-
lines [9] and searched all published literature from
PubMed, Cochrane Library, WHO Regional Databases,
Web of Science, Biosis, Popline, Global Health, Scopus,
and Embase for relevant literature in all available lan-
guages published before December 1, 2012. We used
various combinations of the Medical Subject Heading
Terms (MeSH) and all fields search terms for probiotics
and diarrhea. Given the wide variety of possible thera-
peutic probiotic microorganisms, we also searched using
nomenclature variations of probiotic microorganisms
(e.g., Lactobacillus acidophilus, S. boulardii, etc.). If
reports were unavailable for full-text abstraction, we
made every effort to obtain the unpublished data from
the authors. The complete search strategy is available in
a WebAppendix (Additional file 1).
Inclusion/Exclusion criteria
We included RCTs conducted among children < 5 years of
age with acute diarrhea defined as ≥ 3 loose or watery
stools per day, and a suitable control group. A suitable
control group was defined as a group that was identical to
the treatment group, but received a placebo and/or the
appropriate standard of care for acute diarrhea in lieu of
the probiotic. We sought a representative population of
community-acquired diarrhea and thus excluded studies
that: a) excluded all breastfed children; b) excluded specific
types of diarrhea by etiology or only focused on a specific
etiology; c) included children with a history of or current
antibiotic use; or d) studies that did not evaluate probiotics
alone. We included studies with at least 1 of the following
outcomes: mortality, hospitalizations, severity (stool fre-
quency on day 2, as a secondary measure of severity), or
diarrhea duration.
Abstraction and analysis
We abstracted all studies that met our inclusion/exclusion
criteria into a standardized abstraction form (Additional
file 2). We then organized abstracted data by outcome and
probiotic microorganism. Abstracted variables included
study design, probiotic definition and dosage, point
estimates for both study arms, and relative outcome effect.
Individual study arm characteristics are described in
Table 1, including the probiotic agent, dosage (in colony-
forming units (CFU) or milligrams) and duration of treat-
ment (See Additional file 3 for the full version of Table 1).
Based on the study characteristics, we evaluated the qual-
ity of evidence using the CHERG adaptation of the
GRADE technique [9] (Tables 2 & 3).
For the analysis we grouped all studies by outcome.
Given that the treatment effects may vary by probiotic
organism, we grouped study results by probiotic strain
used as the treatment agent where at least 3 studies
were identified. We then performed subgroup analyses
for the relevant outcomes.
To measure the relative effect we calculated the percent
difference (I-C/C*100) for continuous outcomes. We calcu-
lated the percent difference with the estimated means and
weighted each by the combined sample size of the inter-
vention and control groups by study arm. In the case of
multiple treatment groups and a single control group, we
weighted each study arm by the intervention sample size
and a proportion of the control group sample size. We
then used the percent difference to calculate a weighted
average. For studies that only presented median (IQR), we
estimated the mean using a standard formula for studies
with samples sizes greater than 25 [10]. We used a random
effects meta-analysis to analyze discrete outcomes and
reported the DerSimonian-Laird pooled relative risk and
corresponding 95% confidence interval. The STATA 11
statistical software was used for all analyses [11].
Results
We identified 8,030 titles from the literature search.
After exclusion based on title and abstract, we obtained
and reviewed 134 full papers and included 8 in the final
database (Figure 1). Of these included papers, 6 studies
included an outcome for diarrhea duration [12-17],
5 included stool frequency on day 2 [13,15,17-19] and
2 included a count of diarrhea related hospitalizations
[13,17]. No studies included diarrhea mortality. All
included studies were at least single-blinded RCTs; the
researchers were blinded but in some cases caregivers
were not [13,17]. Based on the combined study limita-
tions and inconsistency of results, we determined the
included studies to be of low to moderate quality
according to GRADE guidelines [9] (Tables 2 & 3).
Effect sizes varied widely across individual studies
(Table 4). Based on the average percent difference, pro-
biotics reduced diarrhea duration by 14.0% (95% CI: 3.8-
24.2%) and stool frequency on day 2 of treatment by
13.1% (95% CI: 0.8 – 25.3%) (Table 2). We found no
effect on diarrhea duration among the Lactobacillus
rhamnosus GG (LGG) only group (16.0%; 95% CI -53.9 –
22.0%) (Table 2). There was no difference in the relative
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risk of hospitalization among children who received pro-
biotics compared with placebo (RR=0.81; 95% CI: 0.42–
1.57) (Table 3 & Figure 2).
Discussion
We conducted a systematic review of RCTs to estimate
the effect of probiotic microorganisms for the treatment of
community-acquired acute diarrhea in children. Results of
this systematic review indicate that probiotics reduced
stool frequency on the second day of treatment by 13.1%.
When we combined all the study arms we found a 14.0%
reduction in diarrhea duration among those who received
probiotics compared to those who received placebo. Of
the 10 study arms included in the analysis, only 1 LGG
arm [13] and 3 probiotic mixtures [12,13,15] found a sig-
nificant reduction in diarrhea duration with effect sizes of
32%, 28.5%, 39.4% and 13.9% respectively (Table 4).
Probiotics did not have an effect on the relative risk of
hospitalization between children in the treatment and con-
trol groups. None of the included studies reported diar-
rhea deaths, thus we were limited to outcomes that
reflected diarrhea morbidity. Based on the available data,
relative risk of hospitalization was the best measure of
severe morbidity, but this outcome had a limited number
of events across the two included studies [13,17] (Table 3).
None of the individual study arms reported a significant
difference in hospital admissions between treatment and
control groups, but studies were not powered for this out-
come measure.
Despite a number of systematic reviews on the efficacy
of probiotic treatment in infectious diarrhea, this is the
first to apply the CHERG guidelines to estimate the
effect of probiotic treatment on community-acquired
acute diarrhea among children for inclusion in the LiST
software. This review follows the CHERG systematic
review methods required of all LiST interventions to
estimate the effect of the intervention on cause-specific
mortality [9]. The LiST tool is designed to provide inter-
national agencies and policymakers with evidence-based
estimations of lives that could be saved with the scale-
up of key interventions [20]. Thus, the implications of
this review are important for programmatic and policy
decisions in the management of childhood diarrheal dis-
ease in low- and middle-income countries (LMIC).
Our review indicates a reduction in diarrhea duration
and stool frequency, which may be indicative of attenuated
Table 1 Study characteristics
Study arms
Intervention Control





56 L. bulgaricus &S. thermophilus (2x108
CFU/g)
180 mL/kg/day infant
formula given after initial oral
rehydration
56 Infant formula acidified
with lactic acid to match
yogurt pH
Canani [13] 100 Lactobacillus GG (6x109 CFU/dose) 2/day for 5 days in 20 ml
water
92 Not described
91 S. boulardii (5x109 live organisms/
dose)
2/day for 5 days in 20 ml
water
92
100 Bacillus clausii (109 CFU/dose) 2/day for 5 days in 20 ml
water
92
97 L. bulgaricus, L. acidophilus, S.
thermophilus, B. bifidum (5x108- 109
CFU/dose)
2/day for 5 days in 20 ml
water
92
91 Enterococcus faecium (7.5x107 CFU/
dose)





65 S. boulardii (200 mg/dose) Every 8 hours in 5ml of cold
liquid





61 Lactobacillus GG (10x109 CFU/day) 1/day w/oral electrolyte
solution
63 Inulin
Lee [15] 50 Lyophilized L. acidophilus and B.
infantis (3x109 CFU of each/day)
1/day for 4 days 50 Not described
Misra [16] 105 Lactobacillus GG (1x109 CFU/dose) 1/day for 10 days 105 Identical placebo
(crystalline microcellulose)







Lactobacillus GG, L. acidophilus, L.
casei, L. plantarum, B. infantis (3x109
CFU/capsule)
3 capsules/ day for 9 days 22 Identical placebo
(maltodextrine)
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intensity of the intestinal infection [21]. These results are
consistent with findings in previous systematic reviews
[3,8]. Previous studies have shown that benefits of probio-
tics on diarrhea may be strain and/or etiology specific
[6,13,22], meaning only certain strains may be efficacious
in the treatment of a particular etiology of diarrhea. Prior
systematic reviews have found larger effect sizes for
probiotic treatment on diarrhea duration than what we
report here [3,6], but they included studies among specia-
lized populations such as young children with confirmed
rotavirus diarrhea or populations of infants who were
completely weaned. Given that the etiologies of most
childhood diarrhea episodes in developing countries are
not confirmed, we designed this review to include only
Table 2 Quality of evidence for treatment of diarrhea with probiotics for diarrhea duration and stool frequency on
day 2







Design Limitations Consistency Generalizability
to population
of interest





Various probiotics: low [12-17]
6(10) RCT Different doses/day; variable
treatment duration; not double
blinded, small n, placebo not
described (-0.5)








Mixtures prevent analysis of
individual effect sizes, not enough
data to make a statement about
each probiotic strain (-0.5)
-14.0 (-24.2 – -3.8%)
Lactobacillus rhamnosus GG: moderate [13,14,16]
3(3) RCT Different doses/day; variable
treatment duration; not double
blinded (-0.5)






Generalizable -16.0 (-53.9 – 22.0%)
Stool frequency (Day 2)
Various probiotics: moderate/low [13,15,17-19]
5(9) RCT Not double blinded, small n,
placebo not described (-0.5)







Mixtures prevent analysis of
individual effect sizes, not enough
data to make a statement about
each probiotic strain (-0.5)
-13.1 (-25.3 – -0.8%)
Diarrhea duration (study arms): LGG (3), S. boulardii (1), Bacillus clausii (1), Enterococcus faecium (1), Mix A*(1), Mix B**(1), Mix C***(1), Mix D****(1)
Stool frequency (study arms): LGG (1), S. boulardii (2), Bacillus clausii (1), Enterococcus faecium (1), L. acidophilus (1), Mix A*(1), Mix B**(1), Mix C***(1)
*L. bulgaricus, L. acidophilus, Streptococcus thermophilus, B. bifidum
** L. acidophilus & Bifidobacteria infantis
*** LGG, L. acidophilus, L. casei, L. plantarum, Bifidobacterium infantis
****L. bulgaricus & S. thermophilus
Table 3 Quality of evidence for treatment of diarrhea with probiotics for hospitalizations
Quality assessment Summary of findings










Intervention Control Relative Risk
(95% CI)
Diarrhea hospitailizations
Various Probiotics: Moderate/Low [13,17]
2(6) RCT Not double blinded, small











Mixtures prevent analysis of
individual effect sizes, not





Hospitalizations (study arm): LGG (1), S. boulardii (1), Bacillus clausii (1), Enterococcus faecium (1), Mix A* (1), Mix C*** (1)
* L. bulgaricus, L. acidophilus, Streptococcus thermophilus, B. bifidum
*** LGG, L. acidophilus, L. casei, L. plantarum, Bifidobacterium infantis
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Figure 1 Results of literature search for studies on treatment of diarrhea with probiotics
Table 4 Percent difference and weight contributed by study and continuous outcome
Probiotic microorganism Study arm by author Percent difference % Weight
Diarrhea duration
Lactobacillus rhamnosus GG Canani [13] -32.0* 10.2
Lactobacillus rhamnosus GG Costa-Ribeiro [14] -2.1 10.6
Lactobacillus rhamnosus GG Misra [16] -9.5 18.0
L. bulgaricus & S. thermophilus Boudraa [12] -28.5§ 9.6
Saccharomyces boulardii Canani [13] -9.1 9.4
Bacillus clausii Canani [13] 2.2 10.2
Enterococcus faecium Canani [13] 0.0 9.4
L. bulgaricus, L. acidophilus, Streptococcus thermophilus, B. bifidum Canani [13] -39.4* 9.9
L. acidophilus & Bifidobacteria infantis Lee [15] -13.9* 8.6
Lactobacillus GG, L. acidophilus, L. casei, L. plantarum, Bifidobacterium infantis Veereman-Wauters [17] -7.5 4.0
Stool frequency (day 2)
Lactobacillus rhamnosus GG Canani [13] -20.0* 12.8
Lactobacillus acidophilus Rafeey [19] 0.0 8.6
Saccharomyces boulardii Canani [13] 0.0 11.9
Saccharomyces boulardii Cetina-Sauri [18] -14.2§ 14.0
Bacillus clausii Canani [13] 0.0 12.8
Enterococcus faecium Canani [13] 0.0 11.9
L. bulgaricus, L. acidophilus, Streptococcus thermophilus, B. bifidum Canani [13] -20.0* 12.5
L. acidophilus & Bifidobacteria infantis Lee [15] -48.6* 10.8
Lactobacillus GG, L. acidophilus, L. casei, L. plantarum, Bifidobacterium infantis Veereman-Wauters [17] -16.7 4.7
Statistically significant differences between groups at the p<0.01 and p<0.05 levels indicated by (*) and (§) respectively for diarrhea duration and stool frequency
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studies that did not exclude based on etiology. To be pro-
grammatically relevant at the community/household level
the intervention must demonstrate efficacy for episodes of
non-specific origin.
As a secondary aim of this review, we evaluated the
efficacy of individual probiotic strains for acute diarrhea
treatment. We evaluated strain-specific differences in
therapeutic properties for probiotics with 3 or more
study arms. Based on the limited number of included
studies and wide variation in probiotic organisms, we
were only able to examine the specific pooled effect of
LGG on diarrhea duration. These results were not found
to be significant. Also, we were not able to separate the
various mixtures of probiotics to evaluate the efficacy by
individual strain or dose.
There are limitations associated with the studies we
included and analysis as it pertains to the CHERG
guidelines. Ideally, we would have included only com-
munity-based studies conducted in LMIC. Because we
only found 5 studies from LMIC and of these 3 reported
diarrhea duration [12,14,16], 2 reported stool frequency
on day 2 [18,19], and none reported diarrhea hospitali-
zations, we chose to include studies from high-income
countries [13,15,17]. No studies were conducted in the
community, all were in outpatient or hospital settings,
and thus results may not be generalizable to home-
based treatment of diarrhea episodes. All included RCTs
had a control group that received a blinded placebo
and/or standard of care, but the placebo substances
were not standardized across studies. We controlled for
potential confounding effects of varying placebos by
excluding studies that used placebos with potential ther-
apeutic properties in treating diarrhea (e.g., prebiotics or
calcium supplements).
In addition, WHO has recommended low osmolarity
ORS, continued feeding, and zinc for the treatment of
diarrhea since 2004 [2]. None of the included studies
provided zinc as part of the recommended treatment.
To best estimate the effect probiotics could have on cur-
rent home management of diarrhea, additional RCTs
should be conducted to compare the currently recom-
mended treatment, ORS, continued feeding, and zinc
supplementation, with and without the addition of
probiotics.
Interventions included in the LiST software are those
that have been shown to reduce cause-specific mortality,
or provide strong evidence of a reduction of severe mor-
bidity among children less than five years of age [9]. We
used the adapted GRADE technique [9] to assess the
quality of evidence associated with the included studies
by outcome. Despite being RCTs the combined quality
score of included studies was low/moderate, primarily
due to small sample size, inadequate blinding, and
reduced generalizability (Tables 2 & 3). Based on the
lack of mortality data, no effect on severe morbidity (i.e.,
hospitalizations), and the low-moderate quality evidence
Figure 2 Forest plot for the effect of probiotics as compared to control on diarrhea hospitalizations Legend: * L. bulgaricus, L.
acidophilus, Streptococcus thermophilus, B. bifidum ** LGG, L. acidophilus, L. casei, L. plantarum, B. infantis
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for mild outcomes (i.e., diarrhea duration and stool fre-
quency), there is insufficient evidence to conclude pro-
biotics for the treatment of diarrhea will reduce diarrhea
mortality, and thus at this time this intervention should
not be included in LiST (Figure 3).
Conclusions
This review highlights important implications for future
research of the therapeutic effectiveness of probiotics,
when compared with rehydration alone, for childhood
diarrhea in LMIC. Community-based RCTs should be
conducted in low- and middle-income countries to
determine the effect of probiotic treatment, when com-
pared with ORS, continued feeding, and zinc - the
recommended treatment for community-acquired acute
diarrhea among children <5 years of age. Furthermore,
cost-effective analyses and qualitative studies should
examine parental acceptance and access to probiotics to
determine the feasibility of probiotic treatment in devel-
oping countries.
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